The effect of cigarette smoking, alcohol consumption and fruit and vegetable consumption on IVF outcomes: A review and presentation of original data

Background - Lifestyle factors including cigarette smoking, alcohol consumption and nutritional habits impact on health, wellness, and the risk of chronic diseases. In the areas of in-vitro fertilization (IVF) and pregnancy, lifestyle factors influence oocyte production, fertilization rates, pregnancy and pregnancy loss, while chronic, low-grade oxidative stress may underlie poor outcomes for some IVF cases. Methods - Here, we review the current literature and present some original, previously unpublished data, obtained from couples attending the PIVET Medical Centre in Western Australia. Results - During the study, 80 % of females and 70 % of male partners completed a 1-week diary documenting their smoking, alcohol and fruit and vegetable intake. The subsequent clinical outcomes of their IVF treatment such as quantity of oocytes collected, fertilization rates, pregnancy and pregnancy loss were submitted to multiple regression analysis, in order to investigate the relationship between patients, treatment and the recorded lifestyle factors. Of significance, it was found that male smoking caused an increased risk of pregnancy loss (p = 0.029), while female smoking caused an adverse effect on ovarian reserve. Both alcohol consumption (β = 0.074, p < 0.001) and fruit and vegetable consumption (β = 0.034, p < 0.001) had positive effects on fertilization. Conclusion - Based on our results and the current literature, there is an important impact of lifestyle factors on IVF clinical outcomes. Currently, there are conflicting results regarding other lifestyle factors such as nutritional habits and alcohol consumption, but it is apparent that chronic oxidative stress induced by lifestyle factors and poor nutritional habits associate with a lower rate of IVF success

Sexto reporte de eventos adversos con tratamientos biológicos en Argentina. Informe del registro BIOBADASAR

Objetivo: actualizar los resultados del registro BIOBADASAR sobre seguridad, duración y causas de interrupción del tratamiento luego de 8 años de seguimiento. Métodos: BIOBADASAR es un registro de seguridad de terapias biológicas establecido por la Sociedad Argentina de Reumatología. Se presenta la descripción de BIOBADASAR 3.0, una cohorte compuesta por 53 centros de Argentina seguidos prospectivamente desde agosto de 2010 hasta enero de 2018

Nanopartículas coloidales de Cu/película compuesta de quitosano obtenida por calentamiento con microondas para aplicaciones de envasado de alimentos

En este artículo, describimos la preparación y caracterización de nanopartículas coloidales de Cu/película compuesta de quitosano (película compuesta) mediante la técnica de fundición en solución con calentamiento por microondas. Se investigaron los efectos de la incorporación de nanopartículas de Cu coloidal sobre la estructura, el comportamiento térmico, la superficie, las propiedades de barrera y la transmisión de luz de la película compuesta. También se probó la actividad antimicrobiana de las películas contra Staphylococcus aureus y Salmonella enterica serovar Typhimurium. La incorporación de nanopartículas de Cu coloidal en la matriz de quitosano mejoró las propiedades de barrera de las películas, disminuyendo la permeabilidad al oxígeno y al vapor de agua y aumentando la protección contra la luz ultravioleta. La película compuesta fue efectiva en la alteración de la pared celular y la reducción de la concentración microbiana en el cultivo líquido para ambas bacterias probadas.In this paper, we describe the preparation and characterization of colloidal Cu nanoparticles/chitosan composite film (composite film) by solution-casting technique with microwave heating. Effects of the incorporation of colloidal Cu nanoparticles on structure, thermal behavior, surface, barrier properties and light transmission of composite film were investigated. The antimicrobial activity of films against Staphylococcus aureus and Salmonella enterica serovar Typhimurium, were also tested. Incorporation of colloidal Cu nanoparticles on chitosan matrix improved the barrier properties of films, decreasing the oxygen permeability as well as water vapor permeability and increasing the protection against UV light. The composite film was effective in alteration of cell wall and reduction of microbial concentration in the liquid culture for both bacteria tested

Development of lymphoma in patients with primary Sjögren Syndrome

Lymphoma is the main complication of primary Sjögren syndrome (pSS). The aim of this study was to describe the prevalence and incidence rate of lymphoma in patients with pSS in eleven centers in Argentina. To determine the frequency of commitment of the domains of the baseline clinical ESSDAI in the patients who developed lymphoma in the course of their follow-up and compare it with the rest of the sample. Methods and findings: We included patients older than 18 years with a diagnosis of pSS according to American College of Rheumatology/European League against Rheumatism (ACR/EULAR)2002/2016 criteria, included in a multi-center Argentine database. Patients diagnosed with another associated autoimmune rheumatic disease were excluded. Six hundred and eighty one patients were included, 95% female, with a mean age of 54.41 years (± 13.70). Sixteen patients presented lymphoma (prevalence: 2.35%, 95% CI: 1.2-3.4%). The average follow-up time was 4.7 years (± 4.94). Six hundread and thirty three patients contributed data for the survival analysis. The incidence rate of lymphoma was 0.54 per 100 patient-years (95% CI: -0,26 a 1,34). The most frequently lymphoma type was MALT. Patients who developed lymphoma had a higher frequency of involvement of most of the domains of the baseline clinical ESSDAI compared to patients who did not present this complication, observing statistically significant differences in glandular (68,75% vs 28.69%, p:0,001), and cutaneous (31.25% vs 10.99%, p: 0.01) domains. The glandular domain of clinical ESSDAI was the main domain associated lymphoma development (H.R: 4.54, 95% CI: 1.57-13.12). Conclusion: This was the first study with data on the population of Argentina about the prevalence of lymphoma in patients diagnosed with Sjogren´s syndrome. The prevalence of lymphoma in our cohort was lower than previously published. Despite observing a lower frequency of lymphoma in our study, we found an association with risk markers described in the literature, such as baseline parotidomegaly and cutaneous involvement.Fil: Schenone, L. N.. Hospital Bernardino Rivadavia. Buenos Aires; ArgentinaFil: Pellet, A. C.. Hospital Bernardino Rivadavia. Buenos Aires; ArgentinaFil: Mamani, M.. Hospital Bernardino Rivadavia. Buenos Aires; ArgentinaFil: Melo, F.. Hospital Bernardino Rivadavia. Buenos Aires; ArgentinaFil: Adrover, M.. Hospital Bernardino Rivadavia. Buenos Aires; ArgentinaFil: Barreira, J.. Hospital Británico. Buenos Aires; ArgentinaFil: Dermarchi, Julia. Hospital Británico. Buenos Aires; ArgentinaFil: Escobar, C. S.. Hospital Británico.Buenos Aires; ArgentinaFil: Santiago, L.. Organización Médica de Investigación. Buenos Aires; ArgentinaFil: Salvatierra, G.. Rheumatology Unit. IPRI. Santiago del Estero; ArgentinaFil: Nitsche, A.. Hospital Alemán; ArgentinaFil: Asnal, C.. Hospital Alemán; ArgentinaFil: Amitrano, C.. Hospital Alemán; ArgentinaFil: Pucci, P.. Hospital Alemán; ArgentinaFil: Crow, C.. Hospital Alemán; ArgentinaFil: Ratti, L.. Clinica Bessone. Buenos Aires; ArgentinaFil: Cruzat, V.. Clinica Bessone. Buenos Aires; ArgentinaFil: Papasidero, S.. Hospital Tornu. Buenos Aires; ArgentinaFil: Caeiro, Francisco. Hospital Privado Centro Médico de Córdoba; ArgentinaFil: Retamozo, Maria Soledad. Hospital Privado Centro Médico de Córdoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Baenas, Diego Federico. Hospital Privado Centro Médico de Córdoba; ArgentinaFil: Riscanevo, Nadia. Hospital Privado Centro Médico de Córdoba; ArgentinaFil: Vélez, S.. Rheumatology Care Offices, Buenos Aires; ArgentinaFil: Juarez, V. R.. Hospital del Milagro, Salta, Argentina; ArgentinaFil: Secco, A.. Hospital Bernardino Rivadavia; Argentin